• S. 515 - A bill to amend title 35, United States Code, to provide for patent reform. S. 610 - A bill to amend title 35, United States Code, to provide for patent reform. H.R. 1260 - To amend title 35, United States Code, to provide for patent reform.
• H.R. 1427 - To amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes. S. 726 - A bill to amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes. H.R. 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes. S. 1213 - A bill to amend title XI of the Social Security Act to provide for the conduct of comparative effectiveness research and to amend the Internal Revenue Code of 1986 to establish a Patient-Centered Outcomes Research Trust Fund, and for other purposes. S. 1259 - A bill to protect all patients by prohibiting the use of data obtained from comparative effectiveness research to deny coverage of items or services under Federal health care programs and to ensure that comparative effectiveness research accounts for advancements in personalized medicine and differences in patient treatment response. S. 1679 - An original bill to make quality, affordable health care available to all Americans, reduce costs, improve health care quality, enhance disease prevention, and strengthen the health care workforce. H.R. 3200 - To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 3962 - To provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes. H.R. 3590 - An act entitled The Patient Protection and Affordable Care Act. S. 1796 - An original bill to provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes.
• H.R. 1706 - To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and for other purposes. S. 369 - A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market.

Duration: January 1, 2007 to December 31, 2009

General Issues: Copyright/Patent/Trademark, Health Issues, Labor Issues/Antitrust/Workplace, Pharmacy, Medicare/Medicaid, Budget/Appropriations

Spending: about $700,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2007: U.S. Senate, House of Representatives, Y Y